Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmacopeia, Inc. (ACCL) (Prev: PCOP) -- Ignore unavailable to you. Want to Upgrade?

To: Susan Rodney who wrote (38)	11/24/1997 12:59:00 AM
From: James Silverman	Read Replies (1) \| Respond to of 179

Sue, Don't get me wrong, I like your company, what you are doing and how much progress you have made. I've heard people question how many combi-chem companies can succeed, with the thought that only one or at least not more than a few can survive. I find this argument extremely weak and believe that there is more than ample room for PCOP, ARQL and a host of others. These companies will go as far as their scientists and mgt can take them and while each appear to have solid foundations, there is certainly room for hosts of others like Versicor, 3DP, molecumetics etc etc etc. Which brings me to my main point, I find it troublesome that PCOP seems so competitive in regards to ARQL and I don't quite fathom why there would be a need. You each have scores of excellent big pharma and biotech partnerships. You each have ample finances and very solid scientific staffs, loaded with talent. So why make a point of letting us know your technology is novel and ARQL's is not? I just don't see why this is necessary as you both have your strengths and weaknesses. ARQL's optimization technology and know- how must be extraordinary as evidenced by a couple of truly incredible JV's they have struck with Wyeth-Ayerst and recently with Sankyo. These are solid guaranteed money deals with very broad scopes and LT royalty potential. The breadth, size and scope of their partnerships, with so many diverse biotechs and big pharma's is a testament to their value. From what I hear, PCOP has superior biology and I found your comment on screening to be very noteful and an asset I assume PCOP is leveraging. Obviously you have the ability to generate massive chemical libraries which is certainly of great value. So just because PCOP has some patented technologies, it doesn't mean your system is any better than anyone elses. For example, Trega has their patented "tea bag" approach and it doesn't seem to have gotten them very far, at least not as far as I can tell. So I guess the point I am trying to politely make is tell me more about PCOP and lighten up a bit on the ARQL talk, from what I can see, you guys can rest on your own laurels and its unnecessary. Caveat: I hold stock in both ARQL and PCOP.

To: Susan Rodney who wrote (38)	2/2/1998 1:45:00 PM
From: James Silverman	Respond to of 179

Sue, So much for the no patent argument. This is a very broad claim relating to parallel synthesis and optimization. Jim 2/2/98 ArQule, Inc. Granted U.S. Patent for Fundamental Approach to Designing and Manufacturing Arrays of Chemical Compounds Logically Ordered, Spatially Arranged Arrays of Compounds Are Facilitating Drug Discovery MEDFORD, Mass., Feb. 2 /PRNewswire/ -- ArQule, Inc. (Nasdaq: ARQL) today announced that it has received from the U.S. Patent and Trademark Office, Patent No. 5,712,171 entitled "Method of Generating a Plurality of Compounds in a Spatially Arranged Array." The patent describes ArQule's novel method to design and manufacture arrays of logically ordered chemical compounds, which enables the Company to derive from its chemical libraries an enormous amount of information based on the characteristics of the constituent compounds. The issuance of the patent awards ArQule broad coverage for one of the most fundamental aspects of its combinatorial chemistry technology. By developing and applying this technology, ArQule has been able to reduce the time required to identify and optimize potential drug candidates to under two years, compared to the industry average of up to six years. In addition, the Company believes that with these advanced technologies, ArQule is able to discover better drugs at lower cost than is possible with traditional methods.